Welcome to the Small Biotechnology Business Coalition Website

The Small Biotechnology Business Coalition (SBBC) is an advocacy organization for America’s small, innovative biotechnology and medical device companies. We advocate for government programs and policies that help small bio-tech firms bring innovative products and technologies to market, thereby creating sustainable economic and job growth, curing or mitigating many diseases, and ultimately reducing health care costs.

DOWNLOAD OUR DOCUMENT SUPPORTING THE INCREASE OF NIH SBIR ALLOCATION

SBIR Reauthorization Deal Reached!

Thanks to all who helped us with the recent SBIR Reauthorization.  While many organizations and individuals contributed to this multi-year effort, SBBC was nearly singularly responsible for the increase in the SBIR and STTR allocation increase.   Over time this will result in about $700 million in new federal funding flowing to small businesses through SBIR.

Senator Mary Landrieu, who led the effort for this bill, said the following in a letter she wrote to SBBC: “I cannot thank you enough for fighting behind the scenes to pass the long-term reauthorization of the SBIR and STTR
programs.  Without the help of our advocacy groups, we would not have the peace of mind knowing that these important programs will be around for another 6 years.”

• Over the past 24 months we organized and held more than 50 meetings with members of the House and Senate Small Business Committees and House Science, Space and Technology Committee, including meetings with members of Congress and Chairman Ralph Hall personally.
• We prepared a comprehensive White Paper and PowerPoint slide set on the case for increasing SBIR at the NIH.
• Our efforts overcame strong opposition from numerous academic lobbying organizations, the White House, BIO, and NVCA.
• Seasoned political observers maintained deep skepticism that we could overcome fierce opposition from the academic lobby.   Even as recently as last summer, BIO’s senior leadership told us that an allocation increase was impossible.
• This equates to a 28% increase in available funding for SBIR phased in over 6 years; at the NIH this amounts to about $200 million in new funding for SBIR/STTR per year after the full increase kicks in!

But we cannot rest on our laurels!  Near term priorities include monitoring the implementation of this new law at the NIH.   We need to ensure, for example, that there is no bias to VC owned companies.

Join SBBC NOW!

By joining the SBBC, YOU are standing up for our industry and promoting the policies that will support growth and success for companies like yours.   We look forward to another successful year of our advocacy efforts on behalf of the NIH SBIR grants program. [find out more]